血小板计数会影响高血小板血和妊娠并发症之间的关联
Bin Yu1, Bin Zhang1, Xiaoya Han1
1Department of Medical Genetics, Changzhou Maternal and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, 16th Ding Xiang Road, Changzhou, 213023, Jiangsu, China.
BMC public health
|June 2, 2023
概括
高胆固醇和低血小板数量增加了孕妇的ICP风险. 相反,高水平的同类半氨酸与高血小板数量降低了GDM风险. 这些因素可以识别高风险怀孕.
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 生物化学 生化学
背景情况:
- 血小板计数和同类半氨酸对妊娠并发症的综合影响尚不清楚.
- 这项研究检查了血小板计数 (PC) 和总同型半氨酸 (tHcy) 对妊娠并发症发生率的协同作用.
研究的目的:
- 为了研究血小板数和总同型半氨酸水平对妊娠并发症风险的联合影响.
- 根据这些生物标志物,确定某些并发症的高或低风险的孕妇的特定子组.
主要方法:
- 分析了11,553名孕妇在分娩时接受血液检查.
- 评估妊娠期糖尿病 (GDM),妊娠期肝脏内胆固醇症 (ICP),妊娠前 (PE) 和妊娠引起的高血压 (PIH) 的患病率.
主要成果:
- 最高的ICP率 (28.6%) 发生在高THC和低PC的女性中.
- 在高THcy和高PC的女性中,GDM发病率最低 (0.6%).
- 在低PC组中,高tHcy显著增加了ICP风险 (OR:3.34).
结论:
- 一个具有高THC和低PC的子组面临着最高的ICP风险.
- 一个具有高THC和高PC的子组具有最低的GDM风险.
- tHcy和血小板计数可以作为孕妇ICP和GDM风险的预测指标.
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
127
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
127
Anticoagulant Drugs: Low-Molecular-Weight Heparins
773
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
773
Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
570
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
570
Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K


